The Medications Worth Taking Seriously — And the One You Can Probably Stop
Statins, blood pressure drugs, and the aspirin reversal
Cardiovascular medicine has some of the largest, most rigorously conducted trial evidence in all of medicine behind it. This section covers the major drug classes plainly, including one significant reversal worth knowing about.
Statins: Among the Most Tested Drugs in Medicine
Statins — a class of medication that lowers LDL (low-density lipoprotein) cholesterol by blocking a liver enzyme involved in producing it — reduce the relative risk of major cardiovascular events by roughly one-fifth for every 1 mmol/L reduction in LDL cholesterol achieved, according to a meta-analysis pooling data from over 170,000 participants across 26 randomised trials, with benefit observed across a wide range of patient risk profiles and no evidence of a lower threshold below which the benefit disappears[14]. The same analysis found no increase in non-cardiovascular death or cancer risk, alongside small but real increases in the incidence of myopathy (muscle symptoms) and new-onset diabetes — a genuine trade-off, but one that favours treatment for most people at elevated cardiovascular risk given the size of the cardiovascular benefit.
Blood Pressure Medication
Several well-established drug classes reliably lower blood pressure and reduce cardiovascular events in large trial populations: ACE inhibitors (which relax blood vessels by blocking a hormone that narrows them), ARBs (a related class that blocks that same hormone's effects more directly), calcium channel blockers (which relax artery walls by limiting calcium entry into their muscle cells), and thiazide diuretics (which lower blood pressure by helping the kidneys remove excess sodium and fluid) — among the most common first-line options. Which specific class is most appropriate depends on individual factors (kidney function, other conditions, side-effect profile) best judged by a prescribing doctor rather than by this guide.
Aspirin: The Reversal Worth Knowing
Daily low-dose aspirin was, for decades, widely recommended as a preventive measure for cardiovascular disease even in people without existing heart disease. A large randomised trial of over 19,000 healthy older adults free of prior cardiovascular disease, dementia, or disability found that daily aspirin did not extend disability-free survival and did not meaningfully reduce cardiovascular events, while significantly increasing the risk of major bleeding[15]. This finding, alongside similar results from other trials, has shifted major guideline bodies away from routinely recommending aspirin for primary prevention (in people without existing cardiovascular disease) — it generally remains appropriate for secondary prevention, in people who have already had a heart attack or stroke, where the bleeding risk is more clearly outweighed by benefit. If you're currently taking daily aspirin without a history of cardiovascular events, this is a genuinely worthwhile conversation to have with your doctor rather than a decision to make unilaterally.
| Medication | Who it's generally for | Key evidence |
|---|---|---|
| Statins | Elevated ApoB/LDL with meaningful cardiovascular risk | ~20% relative risk reduction per 1 mmol/L LDL lowered, across 170,000+ trial participants |
| Blood pressure medication | Blood pressure not controlled by lifestyle alone | Multiple drug classes with large trial evidence for reducing cardiovascular events |
| Low-dose aspirin | Secondary prevention (after a prior event) — not routine primary prevention | ASPREE trial found no net benefit and more bleeding risk in healthy older adults without prior disease |
Section takeaway
Statins and blood pressure medication remain among the best-evidenced interventions in cardiovascular medicine — declining them on principle carries a real, measurable cost for most people at elevated risk. Aspirin is the exception: the evidence has genuinely shifted, and daily aspirin without a prior cardiovascular event is now a conversation worth having, not a default.